Compare LAZ & MMSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LAZ | MMSI |
|---|---|---|
| Founded | 1848 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 4.9B |
| IPO Year | 2005 | 1990 |
| Metric | LAZ | MMSI |
|---|---|---|
| Price | $54.76 | $81.22 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 9 |
| Target Price | $55.38 | ★ $106.22 |
| AVG Volume (30 Days) | ★ 1.0M | 646.3K |
| Earning Date | 01-29-2026 | 02-24-2026 |
| Dividend Yield | ★ 3.51% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.17 | 1.95 |
| Revenue | ★ $3,098,847,000.00 | $1,477,128,000.00 |
| Revenue This Year | $15.79 | $13.67 |
| Revenue Next Year | $12.49 | $6.16 |
| P/E Ratio | ★ $26.25 | $42.14 |
| Revenue Growth | 1.64 | ★ 11.41 |
| 52 Week Low | $31.97 | $78.12 |
| 52 Week High | $58.75 | $110.67 |
| Indicator | LAZ | MMSI |
|---|---|---|
| Relative Strength Index (RSI) | 57.25 | 45.77 |
| Support Level | $50.93 | $79.22 |
| Resistance Level | $58.75 | $82.92 |
| Average True Range (ATR) | 2.20 | 2.07 |
| MACD | 0.25 | 0.21 |
| Stochastic Oscillator | 56.39 | 48.34 |
Lazard Inc has a storied history that can be traced back to 1848. The company's revenue is fairly evenly split between financial advisory, such as acquisition and restructuring advisory, and asset management. The company's asset management business is primarily driven by equities (over 80% of assets under management), has an international focus, and targets institutional clients. By geography, the company earns approximately 60% of revenue in the Americas, 35% in EMEA, and 5% in Asia-Pacific. Lazard has offices across more than 20 countries and over 3,000 employees.
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.